


PRODUCT INFORMATION



Ipsapirone (hydrochloride)

Item No. 22075

CAS Registry No.: 95847-70-4
Formal Name: 2-[4-[4-(2-pyrimidinyl)-1-piperazinyl]butyl]-1,2-benzisothiazol-3(2H)-one, 1,1-dioxide, monohydrochloride
Synonym: TVXQ 7821
MF: C₁₉H₂₃N₅O₃S • HCl
FW: 437.9
Purity: ≥98%
UV/Vis.: λ_{max}: 236, 284 nm
Supplied as: A crystalline solid
Storage: -20°C
Stability: ≥2 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Laboratory Procedures

Ipsapirone (hydrochloride) is supplied as a crystalline solid. A stock solution may be made by dissolving the ipsapirone (hydrochloride) in the solvent of choice. Ipsapirone (hydrochloride) is soluble in organic solvents such as DMSO and dimethyl formamide, which should be purged with an inert gas. The solubility of ipsapirone (hydrochloride) in these solvents is approximately 20 and 10 mg/ml, respectively. Ipsapirone (hydrochloride) is also slightly soluble in ethanol.

Ipsapirone (hydrochloride) is sparingly soluble in aqueous buffers. For maximum solubility in aqueous buffers, ipsapirone (hydrochloride) should first be dissolved in DMSO and then diluted with the aqueous buffer of choice. Ipsapirone (hydrochloride) has a solubility of approximately 0.025 mg/ml in a 1:40 solution of DMSO:PBS (pH 7.2) using this method. We do not recommend storing the aqueous solution for more than one day.

Description

Ipsapirone is a partial agonist of the serotonin (5-HT) receptor 5-HT_{1A} (K_i = 10 nM in hippocampal membranes).¹ It reduces 5-HT release in rat ventral hippocampus *in vivo*.² Low doses of ipsapirone decrease, while high doses increase, extracellular dopamine release in murine nucleus accumbens.³ Extracellular dopamine levels in murine striatum increase following administration of ipsapirone at concentrations >0.1 mg/kg. Ipsapirone has anxiolytic effects *in vivo*, inhibiting foot shock-induced aggression and passive avoidance behavior in rats (ED₅₀s = 2.2 and 0.5 mg/kg, respectively).⁴ Formulations containing ipsapirone have been used to treat depression and borderline personality disorder.⁵

References

1. Rausch, J.L., Johnson, M.E., Kasik, K.E., *et al.* *Neuropsychopharmacology* **31(10)**, 2274-2280 (2006).
2. Traber, J., Davies, M.A., Dompert, W.U., *et al.* *Brain Res. Bull.* **12(6)**, 741-744 (1984).
3. Ichikawa, J. and Meltzer, H.Y. *Brain Res.* **842(2)**, 445-451 (1999).
4. Sharp, T., Bramwell, S.R., and Grahame-Smith, D.G. *Br. J. Pharmacol.* **96(2)**, 283-290 (1989).
5. Glaser, T. and Traber, J. *Naunyn Schmiedebergs Arch. Pharmacol.* **329(3)**, 211-215 (1985).

WARNING

THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

SAFETY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the complete Safety Data Sheet, which has been sent via email to your institution.

WARRANTY AND LIMITATION OF REMEDY

Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 11/10/2023

CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD
ANN ARBOR, MI 48108 · USA

PHONE: [800] 364-9897

[734] 971-3335

FAX: [734] 971-3640

CUSTSERV@CAYMANCHEM.COM
WWW.CAYMANCHEM.COM